NCT06730932View on ClinicalTrials.gov

A Prospective，Single Arm, Multicenter Clinical Study of BTLA Monoclonal Antibody JS004 (B/T Lymphocyte Attenuator Factor Monoclonal Antibody) in Combination With Toripalimab in Patients With Unresectable or Advanced Renal Cell Carcinoma Who Had Failed Previous Immunotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

December 30, 2027

Conditions
Unresectable or Advanced Clear Cell Renal Cell Carcinoma That Has Progressed After Previous Immunotherapy
Interventions
DRUG

JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)

"Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol"

Trial Locations (1)

200127

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER